How much does it cost to change the behavior of health professionals? A mathematical model and an application to academic detailing

Medical Decision Making

Volumn 25, Issue 3, 2005, Pages 341-347

  Gandjour, Afschin ^a   Lauterbach, Karl Wilhelm ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Health care costs; Professional education; Utilization

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ARTICLE; BUDGET; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH PRACTITIONER; HUMAN; MATHEMATICAL MODEL; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL RESEARCH; PHYSICIAN ATTITUDE; PRIMARY PREVENTION; RESOURCE ALLOCATION; SECONDARY PREVENTION; STROKE;

ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; COST-BENEFIT ANALYSIS; EDUCATION, MEDICAL, CONTINUING; EVIDENCE-BASED MEDICINE; GERMANY; GUIDELINE ADHERENCE; HEALTH SERVICES MISUSE; HUMANS; HYPERTENSION; MODELS, ECONOMETRIC; PHYSICIANS, FAMILY; PRIMARY PREVENTION; QUALITY ASSURANCE, HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 18844362394     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X05276858     Document Type: Article

References (20)

1. Davis D, O'Brien MA, Freemantle N, Wolf FM, Mazmanian P, Taylor-Vaisey A. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA. 1999;282(9):867-74.
2. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003;362(9391):1225-30.
3. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8(6):iii-iv, 1-72.
4. Gandjour A, Lauterbach KW. When is it worth introducing a quality improvement program? A mathematical model. Med Decis Making. 2003;23(6):518-25.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
6. Mason J, Freemantle N, Nazareth I, Eccles M, Haines A, Drummond M. When is it cost-effective to change the behavior of health professionals? JAMA. 2001;286(23):2988-92.
7. Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. 2001;10(7):601-15.
8. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998;36(8):1138-61.
9. Berings D, Blondeel L, Habraken H. The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. Eur J Clin Pharmacol. 1994;46(6):501-5.
10. Zentralinstitut für die kassenärztliche Versorgung. Patienten-Arzt-Panel (ADT-Panel) zur Morbiditätsanalyse. Köln, Berlin: ZI; 2001.
11. Zentralinstitut für die kassenärztliche Versorgung. ZI-Panel Nordrhein: Modellrechnung Patienten-/Diagnosebezogener Behandlungs- und Arzneimittelkosten. Köln: ZI; 1998.
12. Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens. 2004;22(3):479-86.
13. Bognar Z, König M, Vossmerbäumer U. Arzneimittel- kostenmanagement durch Pharmakotherapie: Servicepartner Krankenkasse. In: Salfeld R, Wettke J, eds. Die Zukunft des deutschen Gesundheitswesens: Perspektiven und Konzepte. Berlin: Springer-Verlag; 2001. p 141-56.
14. Bundesärztekammer. Ärztestatistik. Available from: http://www. bundesaerztekammer.de/30/Aerztestatistik/02Kurz/Tabelle10.pdf/. Accessed May 22, 2003.
15. Kawachi I, Purdie G. The benefits and risks of treating mild to moderate hypertension. N Z Med J. 1989;102(872):377-9.
16. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J. 2001;141(5):727-34.
17. Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens. 2001;19(1):149-55.
18. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med. 1995;333(21):1392-400.
19. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22(7):554-72.
20. Jamtvedt G, Young JM, Kristoffersen DT, Thomson O'Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2003; (3):CD000259.